<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016561</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01809</org_study_id>
    <nct_id>NCT01016561</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer</brief_title>
  <official_title>A Pilot Study of MR Imaging Based Intracavitary Brachytherapy for Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the&#xD;
      tumor may help in planning radiation therapy and may result in more tumor cells being killed.&#xD;
      Specialized radiation therapy that delivers a high dose of radiation directly to the tumor&#xD;
      may kill more tumor cells and cause less damage to normal tissue. Drugs, such as cisplatin,&#xD;
      may make tumor cells more sensitive to radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE: This clinical trial is studying magnetic resonance imaging-based radiation therapy&#xD;
      and cisplatin in treating patients with stage I, stage II, stage III, or stage IV cervical&#xD;
      cancer.Detailed DescriptionPRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the feasibility of using MRI based treatment planning for intracavitary&#xD;
      brachytherapy treatment planning.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the incidence of early toxicities, specifically genitourinary and&#xD;
      gastrointestinal.&#xD;
&#xD;
      II. To evaluate the incidence of late toxicities, specifically genitourinary and&#xD;
      gastrointestinal.&#xD;
&#xD;
      III. To evaluate local, regional, and distant recurrence rates. IV. To evaluate disease-free&#xD;
      and overall survival rates. OUTLINE: Patients undergo external beam radiotherapy&#xD;
      (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided&#xD;
      intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60&#xD;
      minutes for 5-6 weeks during radiotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 6 weeks, every 4 months for 2&#xD;
      years, and then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual/enrollments&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Using MRI for Intracavitary Brachytherapy Treatment Planning.</measure>
    <time_frame>Completion of study</time_frame>
    <description>Feasibility will be defined if no greater than 10% of patients experience one of the following events: a) patient is unable to tolerate 50% of MRI-based brachytherapy treatments and b) patient experiences any grade 4 acute (&quot;early&quot;) non-hematologic toxicity attributed to brachytherapy. Acute toxicity occurs within 60 days of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Grade 2 and Higher Gastrointestinal and Genitourinary Early Event Rates as Compared to Historical Series.</measure>
    <time_frame>60 days post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>True Pelvis Failure</measure>
    <time_frame>Time to local recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvis Failure</measure>
    <time_frame>Time to loco-regional recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Time to recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time to death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intracavitary balloon brachytherapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiation therapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>EBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy treatment planning/simulation</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>3D-CRT, conformal radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have histologically confirmed squamous cell, adenosquamous or&#xD;
             adenocarcinoma of the cervix&#xD;
&#xD;
          -  Subjects must have non-metastatic FIGO Stage Ia-IVa cervical cancer&#xD;
&#xD;
          -  Claustrophobic subjects must agree to be sedated during MRI procedures&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with an inability to tolerate MR imaging&#xD;
&#xD;
          -  Subjects who have had prior surgery for treatment of disease other than exploratory&#xD;
             laparotomy or biopsy&#xD;
&#xD;
          -  Study subjects who have contraindication to MRI scanning such as but not limited to&#xD;
             subjects with pacemakers, metal fragments in the eye or certain metallic implants&#xD;
&#xD;
          -  Women of childbearing potential who have a positive result on screening serum&#xD;
             pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abramson Cancer Center of the Unviersity of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <results_first_submitted>April 24, 2020</results_first_submitted>
  <results_first_submitted_qc>May 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2021</results_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Despite all possible efforts to contact the PI/study team, no data are available to be reported</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Despite all possible efforts to contact the PI/study team, no data are available to be reported</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of Using MRI for Intracavitary Brachytherapy Treatment Planning.</title>
        <description>Feasibility will be defined if no greater than 10% of patients experience one of the following events: a) patient is unable to tolerate 50% of MRI-based brachytherapy treatments and b) patient experiences any grade 4 acute (&quot;early&quot;) non-hematologic toxicity attributed to brachytherapy. Acute toxicity occurs within 60 days of therapy.</description>
        <time_frame>Completion of study</time_frame>
        <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Using MRI for Intracavitary Brachytherapy Treatment Planning.</title>
          <description>Feasibility will be defined if no greater than 10% of patients experience one of the following events: a) patient is unable to tolerate 50% of MRI-based brachytherapy treatments and b) patient experiences any grade 4 acute (&quot;early&quot;) non-hematologic toxicity attributed to brachytherapy. Acute toxicity occurs within 60 days of therapy.</description>
          <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Grade 2 and Higher Gastrointestinal and Genitourinary Early Event Rates as Compared to Historical Series.</title>
        <time_frame>60 days post treatment</time_frame>
        <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Grade 2 and Higher Gastrointestinal and Genitourinary Early Event Rates as Compared to Historical Series.</title>
          <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>True Pelvis Failure</title>
        <time_frame>Time to local recurrence</time_frame>
        <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>True Pelvis Failure</title>
          <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pelvis Failure</title>
        <time_frame>Time to loco-regional recurrence</time_frame>
        <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Pelvis Failure</title>
          <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Time to recurrence</time_frame>
        <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>he study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Time to death</time_frame>
        <population>Not enough patients were accrued to the study for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Not enough patients were accrued to the study for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The study was terminated and the PI has left the institution. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.&#xD;
intracavitary balloon brachytherapy&#xD;
external beam radiation therapy&#xD;
intensity-modulated radiation therapy&#xD;
radiation therapy treatment planning/simulation&#xD;
3-dimensional conformal radiation therapy&#xD;
Cisplatin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lilie Lin, MD</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-662-6515</phone>
      <email>lin@xrt.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

